Highlights - Baida Group has experienced a significant short-term stock price increase, indicating potential risks of subsequent declines [1][5] Performance - China Pacific Insurance reported a 9.4% year-on-year increase in premium income for Pacific Life Insurance in the first 11 months [13] Shareholding Changes - Hu塑股份 plans to reduce its shareholding by no more than 2% [14] - Funeng Technology intends to reduce its shareholding by no more than 2% [15] Share Buybacks - Action Education plans to repurchase shares worth between 20 million to 25 million [16] - Nova Star Cloud intends to repurchase shares worth between 75 million to 150 million [17] Contract Wins - China XD Electric's subsidiary won a project worth 1.005 billion for the Southern Power Grid [18] - Poly Union's wholly-owned subsidiary won a project worth 1.528 billion [19] Major Investments - Zhongke Electric plans to invest approximately 7 billion to build an integrated project for producing 300,000 tons of lithium-ion battery anode materials annually [20] -沃尔核材 plans to invest no more than 1.5 billion to expand the Shuikou Industrial Park [21] - Xiechuang Data intends to procure servers worth no more than 9 billion to provide cloud computing services for clients [22] Other News - Jiayuan Technology's chairman has lifted the order for investigation [23] - Jiangte Electric plans to cancel the mining rights for lithium-containing ceramic stone in the Lion Ridge mining area [24] - Haili Biological's subsidiary has obtained a registration certificate for its products in Indonesia [25] Overseas Listings - Meg Intelligent has received approval from the China Securities Regulatory Commission for issuing overseas listed foreign shares (H shares) [3] - Dazhu CNC has also received approval for issuing overseas listed shares (H shares) [4][26]

证券日报网讯 12月16日晚间，海利生物发布公告称，公司2025年第三次临时股东会审议通过《关于收 购控股子公司少数股东权益的议案》。 （文章来源：证券日报） ...

Group 1 - Action Education plans to repurchase shares worth between 20 million to 25 million yuan at a price not exceeding 45 yuan per share for employee stock ownership plans or equity incentives [1] - Fulin Technology's shareholders plan to reduce their holdings by up to 2% of the company's total shares, amounting to a maximum of 24.44 million shares starting from December 22, 2025 [2] - Huashu shares' shareholders intend to reduce their holdings by up to 1% of the company's total shares, which is a maximum of 35.94 million shares [3] Group 2 - Silan Microelectronics has obtained a filing certificate for its 12-inch high-end analog integrated circuit chip manufacturing production line project, with an investment of 10 billion yuan and a monthly production capacity of 20,000 wafers [4] - Aerospace Information confirms that its main business does not involve commercial aerospace and that its operations are normal without significant changes [5] - Qinglong Pipe Industry signed a supply contract worth 294 million yuan for PCCP and pressure steel pipes, accounting for 10.43% of its 2024 revenue [6] Group 3 - Huaxin Precision plans to invest up to 1 billion yuan of idle funds in low-risk financial products [7] - Hainan Rubber received insurance compensation totaling approximately 26.65 million yuan for rubber income and tree insurance [8] - Lianmei Holdings announced the suspension of its subsidiary Fulin Thermal Power due to economic slowdown and reduced customer demand [9] Group 4 - Ruifeng Bank has been approved to issue up to 2.5 billion yuan in secondary capital bonds to enhance its capital and risk resistance [11] - China Pacific Insurance reported a 9.4% year-on-year increase in premium income for its life insurance subsidiary, totaling 250.32 billion yuan [12] - Sunshine Nuohuo signed an agreement with Peking University to establish a joint laboratory for innovative drug development [13] Group 5 - Century Huatong completed the cancellation of 56.12 million repurchased shares, reducing its total share capital from 7.428 billion to 7.372 billion shares [14] - Yaxin Security received a government subsidy of 3 million yuan [15] - Haili Biology's subsidiary received registration certification for a bone repair material in Indonesia [16] Group 6 - Yian Technology's subsidiary secured a major project for magnesium alloy components worth 430 million yuan, expected to start production by the end of March 2026 [17] - Jiangte Electric plans to contest the proposed cancellation of its lithium-containing mining rights [18] - COFCO Technology announced the resignation of its deputy general manager due to work changes [19] Group 7 - Fangsheng Pharmaceutical passed the GMP compliance inspection for its raw material production lines [21] - Bohai Ferry announced the resignation of two deputy general managers for personal and age-related reasons [22] - ST Fuhua appointed a new general manager [23] Group 8 - Huazhong CNC received project funding of 17.7 million yuan, accounting for 31.97% of its audited net profit for 2024 [24] - Oppein Home used 15 million yuan of idle funds to purchase a large time deposit with a 0.9% annual yield [25] - China General Nuclear Power's Ningde Unit 6 has begun full construction, utilizing Hualong One technology with a capacity of 1210 MW [26] Group 9 - Jiayuan Technology's chairman has had the investigation order lifted, and the company is operating normally [27] - Fulaixin Materials' application for a specific stock issuance has been approved by the Shanghai Stock Exchange [28] - Shuhua Sports plans to invest up to 500 million yuan in a health industry park project [29] Group 10 - Rhine Biology's stock will continue to be suspended due to ongoing control change and asset acquisition plans [30] - Haishi Science received approval for clinical trials for four innovative drugs targeting various diseases [31] - Hangcai Co. plans to repurchase shares worth between 50 million to 100 million yuan at a price not exceeding 80 yuan per share [32] Group 11 - Yinxin Technology received a cash dividend of 18 million yuan from its subsidiary [33] - Tianfulong plans to increase its wholly-owned subsidiary's capital by 580 million yuan [34] - Poly United's subsidiary won a bid for a stripping project worth 1.528 billion yuan [35] Group 12 - Minglida's deputy general manager resigned due to health reasons [36] - ST Guohua appointed a new deputy general manager [37] - China Xidian's subsidiaries won contracts totaling 1.005 billion yuan for Southern Power Grid projects [38]

证券代码：603718 证券简称：海利生物 公告编号：2025－059 上海海利生物技术股份有限公司 关于控股子公司产品在印度尼西亚获得注册证的公告 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 注册证编号：KEMENKES RI AKL 30602520601 产品名称：GORORISE Natural Bone Grafting Material 证件有效期：2025.12.10-2026.12.09 产品分类：无源无菌/D 级 能力的植入性医疗器械产品，其具有较为广阔的临床应用潜力及市场空间。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 上海海利生物技术股份有限公司（以下简称"公司"）控股子公司陕西瑞盛 生物科技有限公司（以下简称"瑞盛生物"）于 2025 年 8 月向印度尼西亚卫生部 (以下简称"MOH")递交了瑞盛生物 GORORISE Natural Bone Grafting Material （GORORISE 天然骨移植材料）产品的注册申报资料。瑞盛生物于近日收到 MOH 通知，瑞盛生物的 GORORISE 天然骨移植材料产品获得 MOH 的批 ...

上海市通力律师事务所(以下简称"本所")接受上海海利生物技术股份有限公司(以下 简称"公司")的委托, 指派本所张征轶律师、徐安昌律师(以下简称"本所律师")根据《中 华人民共和国公司法》《中华人民共和国证券法》《上市公司股东会规则》等法律法规和规 范性文件(以下统称"法律法规")及《上海海利生物技术股份有限公司章程》(以下简称"公 司章程")的规定就公司 2025 年第三次临时股东会(以下简称"本次股东会")相关事宜出 具法律意见。 本所律师已经对公司提供的与本次股东会有关的法律文件及其他文件、资料予以了核查、 验证。在进行核查验证过程中, 公司已向本所保证, 公司提供予本所之文件中的所有签署、 盖章及印章都是真实的, 所有作为正本提交给本所的文件都是真实、准确、完整和有效的, 且文件材料为副本或复印件的, 其与原件一致和相符。 在本法律意见书中, 本所仅对本次股东会召集和召开的程序、出席本次股东会人员资格 和召集人资格及表决程序、表决结果是否符合法律法规和公司章程的规定发表意见, 并不 对本次股东会所审议的议案内容以及该等议案所表述的事实或数据的真实性和准确性发表 意见。 本所及本所律师依据法律法规及本法 ...

证券代码：603718 证券简称：海利生物 公告编号：2025-060 上海海利生物技术股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 审议结果：通过 表决情况： | | 同意 | | 反对 | | 弃权 | | | --- | --- | --- | --- | --- | --- | --- | | 股东类型 | 票数 | 比例（%） | 票数 | 比例 | 票数 | 比例 | | | | | | （%） | | （%） | | A 股 | 257,786,632 | 99.3730 | 1,505,370 | 0.5802 | 121,030 | 0.0468 | (二) 涉及重大事项，5%以下股东的表决情况 | 议 | 议案名称 | 同意 | | 反对 | | 弃权 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 案 | | 票数 | 比例（%） | 票数 | 比 ...

Core Viewpoint - Hai Li Biological (603718.SH) announced that its subsidiary, Ruisheng Biological, received approval from the Indonesian Ministry of Health (MOH) for its GORORISE Natural Bone Grafting Material, indicating a significant milestone in expanding its product offerings in the Southeast Asian market [1] Group 1: Product Development and Approval - Ruisheng Biological submitted the registration application for GORORISE Natural Bone Grafting Material to the Indonesian MOH in August 2025 [1] - The GORORISE product is an animal-derived bone repair material that closely resembles human natural bone tissue in composition and microstructure [1] - The product is designed for maxillary bone defect repair and promotes new bone generation through its interconnected porous structure and natural components, showcasing strong potential for clinical application and market expansion [1] Group 2: Regulatory Milestones - GORORISE Natural Bone Grafting Material received its Class III medical device registration certificate from the National Medical Products Administration of China in December 2013 [1] - The product also obtained a Class D medical device registration certificate in Indonesia in December 2025 [1]

Group 1 - The core point of the article is that Haili Biological (603718.SH) announced that its subsidiary, Shaanxi Ruisheng Biotechnology Co., Ltd., has received approval from the Indonesian Ministry of Health for its GORORISE Natural Bone Grafting Material [1] - The GORORISE Natural Bone Grafting Material is an animal-derived bone repair material that closely resembles human natural bone tissue in composition and microstructure [1]

Group 1 - The core point of the article is that Haili Biological's subsidiary, Shaanxi Ruisheng Biotechnology Co., Ltd., has received approval from the Indonesian Ministry of Health for its GORORISE Natural Bone Grafting Material [1] - The GORORISE product is an animal-derived bone repair material that closely resembles human natural bone tissue in composition and microstructure [1]

南方财经12月15日电，海利生物(603718.SH)收购子公司陕西瑞盛生物41%股权一事引发监管关注，上 海证券交易所下发监管工作函，聚焦标的公司业绩下滑与评估作价合理性问题。问询指出，瑞盛生物 2025年第三季度仅实现营业收入2677万元、净利润929万元，较前两个季度大幅下滑，要求海利生物说 明本次交易评估作价是否合理，前次评估预测与标的公司最新经营业绩及趋势是否存在较大差异。 海利生物回应称，瑞盛生物三季度业绩下滑主要受两方面影响：一是2025年5月起不再享受3%简易征收 增值税优惠，改为13%税率征收，且进项税抵扣较少；二是市场准入门槛降低引发"价格战"，6月产品 价格触底后，相关影响集中在三季度体现。公司表示，本次交易评估报告虽以6月30日为基准日，但9月 出具时已充分考虑上述因素，将瑞盛生物估值从17亿元下调至9.74亿元。同时指出，瑞盛生物销售 呈"脉冲式"规律，四季度业绩集中在12月体现，且11月产品单价已回升，前期降价不利影响逐步消化， 当前经营符合预期，评估预测与最新业绩趋势无较大差异，交易作价合理。 ...